Subscribe today and save 57%

Investors Chronicle print and digital editions

Nilushi Karunaratne

Full Year Results

Bioventix looks to next growth phase

The antibody developer believes its troponin assays will drive future momentum

Company News

Full access for just £3.37 a week:

• Tips and recommendations - to beat the market
• Portfolio clinic & Mr Bearbull - build a well-planned portfolio
• Expert tools - track and manage investments effortlessly
• Plus free delivery to your home or office

Subscribe Now

Nilushi Karunaratne

Bioventix looks to next growth phase

Equity research quality declines under Mifid II

River and Mercantile hindered by timing

Intertek rides regulation wave

AA dips on FCA report

Small is mighty for Speedy Hire

Menzies’ chairman ups stake

Ceres looks to commercialisation

Construction slows as Brexit fog thickens

Alfa’s worsening outlook

Allergy looks to future trials

AA's debt still sky high

Charles Taylor soars on takeover bid

Turbulent times for John Menzies

Kier’s long way back

Subscribe today